Extraskeletal Osteosarcoma: An International Rare Cancer Network Study

Area of Science:

• Oncology
• Rare Cancers
• Surgical Pathology

Background:

• Extraskeletal osteosarcoma (ESOS) is a rare malignant tumor.
• Understanding ESOS characteristics and treatment outcomes is crucial for improving patient care.

Purpose of the Study:

• To characterize an international cohort of patients with extraskeletal osteosarcoma (ESOS).
• To analyze treatment strategies and survival outcomes for ESOS.

Main Methods:

• Retrospective data collection via the Rare Cancer Network.
• Analysis of patient demographics, tumor characteristics, multimodality treatment, and survival status.

Main Results:

• Thirty-seven ESOS patients were identified, predominantly with high-grade (86%) and advanced-stage (73%) disease.
• Multimodality treatment, including surgery (85%) and chemotherapy (neoadjuvant 38%, adjuvant 41%), was common.
• Overall survival was impacted by stage IV disease, lack of surgery, and larger primary tumor size (>10 cm).
• Disease-free survival was significantly worse with larger primary tumor size (>10 cm) and older age.

Conclusions:

• Multimodality treatment is standard for localized ESOS, though neoadjuvant therapy indications require further clarification.
• Primary tumor size greater than 10 cm and older age are significant negative prognostic factors for disease-free survival in ESOS.